Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Dorritie, K.A.
23  Ergebnisse:
Personensuche X
?
1

Overall survival in classic Hodgkin lymphoma pts who progre..:

Desai, S. H. ; Spinner, M. ; Evens, A. M....
Hematological Oncology.  41 (2023)  S2 - p. 366-368 , 2023
Link: https://doi.org/10.1002/..
 
?
2

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology.  41 (2023)  S2 - p. 60-62 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Efficacy of brentuximab consolidation by metabolic response..:

Desai, S. H. ; Smith, A. ; Spinner, M....
Hematological Oncology.  41 (2023)  S2 - p. 361-362 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MA..:

Wang, Y. ; Jain, P. ; Locke, F....
HemaSphere.  6 (2022)  - p. 1042-1043 , 2022
Link: https://doi.org/10.1097/..
 
?
5

PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/..:

Diefenbach, C ; Budde, E ; Chavez, J...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUC..:

Wierda, W. G. ; Dorritie, K. A. ; Munoz, J....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTA..:

Siddiqi, T. ; Dorritie, K.A. ; Soumerai, J.D....
Hematological Oncology.  37 (2019)  S2 - p. 109-110 , 2019
Link: https://doi.org/10.1002/..
 
?
8

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MA..:

Wang, Y ; Jain, P ; Locke, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430474/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
9

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MA..:

Y. Wang ; P. Jain ; F. Locke...
http://journals.lww.com/10.1097/01.HS9.0000847488.86807.da.  , 2022
Link: https://doi.org/10.1097/..
 
?
10

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) With R..:

Shah, Nirav N. ; Siddiqi, Tanya ; Maloney, David G....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S353-S354 , 2024
Link: https://doi.org/10.1016/..
 
?
11

Lisocabtagene maraleucel in chronic lymphocytic leukaemia a..:

Siddiqi, Tanya ; Maloney, David G ; Kenderian, Saad S...
The Lancet.  402 (2023)  10402 - p. 641-654 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Oral Abstract: CLL-094 Lisocabtagene Maraleucel (liso-cel) ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S146 , 2023
Link: https://doi.org/10.1016/..
 
?
13

Overall survival of patients with cHL who progress after au..:

Desai, Sanjal H. ; Spinner, Michael A ; Evens, Andrew M....
Blood Advances.  7 (2023)  23 - p. 7295-7303 , 2023
Link: https://doi.org/10.1182/..
 
?
14

Checkpoint inhibitor‐based salvage regimens prior to autolo..:

Desai, Sanjal H. ; Spinner, Michael A. ; David, Kevin...
American Journal of Hematology.  98 (2023)  3 - p. 464-471 , 2023
Link: https://doi.org/10.1002/..
 
?
15

CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S320-S321 , 2023
Link: https://doi.org/10.1016/..
 
1-15